ArticleInternational journal of radiation oncology, biology, physics2017
Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer.
Article in International journal of radiation oncology, biology, physics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a systematic review.Esophagus : official journal of the Japan Esophageal Society · 2023Pooled it
- Efficacy and Safety in Proton Therapy and Photon Therapy for Patients With Esophageal Cancer: A Meta-Analysis.JAMA network open · 2023Pooled it
- Article
- Vertebral body dosimetry associated with hematologic toxicities and survival in esophageal squamous-cell carcinoma treated with chemoradiotherapy plus immunotherapy.Frontiers in immunology · 2026Article
- Proton beam therapy for esophageal cancer compared to existing treatments, including X-ray therapy and surgery.World journal of gastrointestinal surgery · 2025Review
- Advanced esophageal cancer with bone metastases: Prognostic biomarkers and palliative treatment.Heliyon · 2024Review
- Proton Therapy in the Management of Luminal Gastrointestinal Cancers: Esophagus, Stomach, and Anorectum.Cancers · 2022Review
- Current status and application of proton therapy for esophageal cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021Review
- Proton therapy for patients with esophageal cancer: History, characteristics, clinical outcome and future direction of proton beam therapy.Global health & medicine · 2021Review
- Review of clinical results of charged-particle therapy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2021Review
- Association of Chemoradiotherapy With Thoracic Vertebral Fractures in Patients With Esophageal Cancer.JAMA network open · 2020Article
- Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer.JAMA oncology · 2020Article
- Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.Esophagus : official journal of the Japan Esophageal Society · 2020Article
- Article
- Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity.Journal of gastrointestinal oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
purposeRadiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes. Proton therapy has been shown to significantly reduce HT in lung cancer patients receiving concurrent chemotherapy. Therefore, we investigated the potential of bone marrow sparing with protons for esophageal tumors. METHODS AND MATERIALS: Twenty-one patients with mid-esophageal cancer who had undergone conformal radiation therapy (3D50) were selected. Two surrogates for bone marrow were created by outlining the thoracic bones (bone) and only the body of the thoracic vertebrae (TV) in Eclipse. The percentage of overlap of the TV with the planning treatment volume was recorded for each patient. Additional plans were created retrospectively, including a volumetric modulated arc therapy (VMAT) plan with the same dose as for 3D50; a VMAT SIB plan with a dose prescription of 62.5 Gy to the high-risk subregion within the planning treatment volume; a reoptimized TV-sparing VMAT plan; and a proton therapy plan with the same SIB dose prescription. The bone and TV dose metrics were recorded and compared across all plans and variations with respect to PTV and percentage of overlap for each patient.
resultsThe 3D50 plans showed the highest bone mean dose and TV percentage of volume receiving ≥30 Gy (V
conclusionsThe results of the present study have shown that proton therapy can reduced bone marrow toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.